NZ-US Financials November 2025
Resonote Financial Model
Edit values by clicking the ✏️ icon. All corrections implemented per COO feedback.
Note: Month numbering baseline is 1=Feb 2026. This is used throughout all formulas for consistency.
All amounts in NZD per month. ✅ Updated to 6 roles per COO requirements.
Monthly consultant fees in NZD. Some scale with subscriber count.
Monthly infrastructure costs in NZD. Data Centre scales with subscribers.
USA operations begin Month 6 (July 2026). All amounts in USD per month.
Begins Month 24 (January 2028). Annual salaries in USD.
Begins Month 30 (July 2028). Annual salaries in USD.
Begins Month 36 (January 2029). Annual salaries in USD.
Executive operations, regulatory compliance, and platform infrastructure support roles.
Facilities / IT Infrastructure Manager
Sales Operations Coordinator
Marketing / Content Manager
Web / Platform Support Engineer
Regulatory & Compliance Officer
This overview is calculated automatically from the Assumptions tab.
The USD $8.1M capital injection appearing in July 2026 (Month 6) represents the Resonote BioTech Inc. Capital Raise — funding we are seeking from a US State partner, either directly through state programs or via investor partners introduced through state relationships (i.e. Bank of America's J. Golden Moore is facilitating in Utah).
What the $8.1M Comprises:
This is structured as two distinct funding tranches:
1. Clinical Study Funding: USD $3.1M
This funds the VA Phantom Limb Pain clinical trial (N=180 veterans) from July 2026 through September 2027. As detailed in the Clinical tab, the trial runs 15 months with milestone-based disbursements totalling approximately $3M. This may come as a philanthropic grant (such as from a foundation like Huntsman) or through state clinical infrastructure support — the Utah proposal specifically references underwriting the clinical study end-to-end, including principal investigator sponsorship, ethics review, devices, recruitment, monitoring, and publication costs.
2. Resonote Operations Funding: USD $5.0M
This capitalises Resonote BioTech Inc. (Delaware) to execute US market entry and scale operations. It covers headquarters establishment, the Utah Secure Operations Centre staffing (18→28→38 FTE across three phases), US team hiring, platform completion (Android/DC2), and working capital through to profitability.
Why the Table Shows Both OptiRTP and Resonote Drawdown:
The model reflects our dual-entity structure where both companies operate as an integrated unit:
OptiRTP Limited (NZ) remains a cost centre, owning the IP and providing ongoing technical services, platform maintenance, and NZ-based support functions. It continues drawing operating costs monthly (shown in the "OptiRTP Costs" column) — funded initially by the NZ raise (NZD $2.3M / ~USD $1.36M in Month 1), then offset by the $30 USD per subscriber per month licence fee flowing back from Resonote (shown in the "License Rev" column). The "Net OptiRTP" column shows OptiRTP's actual cash draw after receiving licence revenue.
Resonote BioTech Inc. (USA) is the revenue centre and customer-facing entity. The $8.1M injection funds its operational ramp-up, clinical trial execution, and the Utah SOC build-out (shown in the Resonote column from Month 6 onward).
Both entities' costs flow through the consolidated cash position because this represents the total capital requirement to execute our US expansion and clinical pathway. The model shows investors and state partners the complete picture — not just US costs in isolation, but the total enterprise burn rate and capital runway.
⚠️ Important Distinction from NZ Raise:
This USD $8.1M is separate from and in addition to the NZD $2.3M OptiRTP raise currently closing. The NZ raise (injected Month 1 / February 2026) provides bridge capital and operational runway to reach the US market and secure state partnerships. The US raise in Month 6 then provides the substantive capital for clinical execution and commercial scaling.
OptiRTP NZ costs are calculated from the Assumptions tab.
OptiRTP receives $30 USD per subscriber per month as a license fee from Resonote USA, which offsets operating costs.
All amounts in NZD per month. ✅ Reduced to 6 roles per COO requirements.
Monthly consultant fees in NZD. Some scale with subscriber count.
Monthly infrastructure costs in NZD
Resonote USA costs are calculated from the Assumptions tab. ✅ Formula errors in months 27-28 FIXED.
USA operations begin Month 6 (July 2026). All amounts in USD per month.
✅ Fixed: Months 27-28 now maintain proper expenditure levels with no unexpected drops.
This biomarker-anchored autonomic neuromodulation study evaluates non-opioid therapy for veterans with phantom limb pain, and autonomic dysfunction. Trial structure interfaces directly with VA/CMS reimbursement pathways and regulatory validation requirements.
🎖️ Critical Mission: Veteran Mental Health Recovery
This clinical trial represents hope for veterans experiencing chronic phantom limb pain. Lives depend on the accuracy of this financial model to ensure uninterrupted funding and operational continuity throughout the trial period.
Validated by Lindus Health • Draft updated: November 17, 2025
Study Framework
- Total Participants: 180 (120 treatment, 60 control)
- Condition: Phantom Limb Pain (PLP)
- Population: U.S. Veterans (combat and non-combat amputees)
- Duration: 20-week total protocol (4-week baseline, 12-week active use, 4-week follow-up)
- Setting: Charlie Norwood VA Medical Center, Augusta GA
Measurement Design
- PROMIS Tools: Pain Interference, Fatigue, Sleep Disturbance, Emotional Distress
- Cadence: Weekly self-reporting + biometric sync throughout study duration
- Biometrics: Daily Garmin sync (HRV, Resting HR, Sleep %, Body Battery)
- Utilization Metrics: Medication refills, MME, facility visits
Control Methodology
- Control Group: Identical app/earbud use with inert modulation
- Adherence Target: ≥ 80% active completion rate
- Monitoring: ePRO via mobile; cryptographically verified logs
Study Aims & Validation Endpoints
- Demonstrated reduction in PROMIS Pain Interference T-scores
- Observed improvement in HRV and resting heart rate trends
- Reduction in medication usage and facility visit frequency
- Audit-ready data aligned with FDA Class I and CMS review thresholds
This trial structure is built to support quality-of-life and autonomic regulation in PLP-affected veterans. The protocol is designed to produce meaningful insights into pain reduction, utilization drop-off, and clinical effect validation suitable for CMS and VA coverage analysis.
The randomized controlled trial evaluates the effectiveness of OptiRTP's neuromodulation system among 180 veterans experiencing chronic phantom limb pain at the Charlie Norwood VA Medical Center in Augusta, Georgia.
⚠️ Why Veterans Matter
Every delay in trial execution could result in veteran suicide. This technology can save their lives, but only if the financial model ensures uninterrupted trial operations.
Control & Adherence
Control and adherence protocols are Identical: dual blind attention-sham (45 percent vs 55 percent duty cycle), reducing expectancy bias and maximizing ethical response. Adherence is 91 to 95 percent is both levels (as evidenced via remote download). Automated scripts ensure ongoing 4-week correlation. EBM usage then sent to outcomes. Therapy heat, active compliance via real-time alerts, C3 Events (with 99.34%, adding >$3 patent to breach study integrity pathway to FDA Class II (510k), seeking PMA project co-deployed Reasonable target.
Jul 2026 - Pre-Enrollment
Finalize trial protocols, complete IRB approvals, recruitment begins, baseline assessments, data infrastructure setup
Aug 2026 - Dec 2026 - Patient Enrollment
Active recruitment of 180 veterans, baseline assessments, randomization, device setup/training, data collection begins
Nov 2026 - APR 2027 - Active Treatment Phase
12-week active intervention, continuous data collection, week 4 assessments, week 12 assessments, patient data analysis, PRAMS surveys
Apr - Sep 2027 - Observation Phase
Follow-up data, primary outcome analysis, secondary outcome analysis, publication data quality review, manuscript preparation
🎯 Jan 2028 - Results Publication & Impact
High-visibility publication establishes regulatory cornerstone for: FDA Class II clearance pathway (510(k) or De Novo), CMS Coverage with Evidence Development (CED), VA national formulary inclusion, and state Medicaid reimbursement precedent. Every data point translates directly into reimbursement algorithms and regulatory policy.
Biomarker Validation (Garmin Health API)
- Heart Rate Variability (HRV): Expected ↑15-25%
- Resting Heart Rate: Expected ↓5-10 bpm
- Deep Sleep Duration: Expected ↑10-20%
Patient-Reported Outcomes (PROMIS-NIH)
- Pain Interference Scale: Target ≥6 T-point improvement
- Sleep Disturbance Scale: Target ≥6 T-point improvement
- Global Health Score: Composite improvement tracking
Economic Endpoints (VA Electronic Records)
Dual-layer design creates perception-to-physiology bridge: subjective PROMIS scores validated against objective biometric data, producing auditable evidence for regulators (safety/efficacy) and payors (utilization reduction).
Milestone-Linked Payout Schedule
| Month | Milestone | Category | Description | Payout |
|---|---|---|---|---|
| Jul 2026 | Schedule + Kickoff | Start-Up | IRB prep, Protocol finalization, Platform build | $400,000 |
| Aug | Enrollment Launch | Patient Recruitment | Digital campaigns, screening, consent | $300,000 |
| Sep | First 60 randomized | Operational | Virtual site setup, device shipping, ePRO | $250,000 |
| Oct | 120 participant mark | Midpoint Trigger | Recruitment milestone achieved | $225,000 |
| Nov | Treatment Phase Peak | Intervention Delivery | Monitoring, adherence checks | $225,000 |
| Dec | 50% data capture | Monitoring | Week 6 assessments, Garmin sync | $200,000 |
| Jan 2027 | 75% data lock | Clinical Ops | Biostat review, DSMB prep | $200,000 |
| Feb | Final visit for all | Close-Out Trigger | Last participant out (LPO) | $225,000 |
| Mar | Data Freeze | Data Lock | eTMF closure, raw data processing | $225,000 |
| Apr | Primary analysis | Biostatistics | Endpoint analysis, QA, AE review | $200,000 |
| May | Draft CSR | Medical Writing | Clinical Study Report prep | $200,000 |
| Jun | Final CSR | Deliverable | Pub-ready data package | $150,000 |
| Jul | Publication submission | Legacy Prep | Journal sub, FDA planning | $100,000 |
| Aug | Audit readiness | QA/QC | Site close-out, data review | $100,000 |
| Sep | Reimbursement prep | Strategic | CMS/VA path validation | $100,000 |
| TOTAL | $3,100,000 | |||
Variable milestone-based costs from $400K to $100K (Jul 2026 - Sep 2027) = $3.1M total
Resonote BioTech's US operational nerve center: Executive coordination, clinical operations support, regulatory compliance, sales infrastructure, and 24/7 platform reliability. This staffing model scales across three operational phases aligned with subscriber growth, clinical validation, and market expansion milestones.
The Utah SOC functions as Resonote BioTech's comprehensive US operational headquarters:
✅ Executive & Administrative
Leadership coordination, board support, investor relations infrastructure
✅ Clinical & Regulatory
HIPAA, CMS, VA, and FDA documentation protocols and audit readiness
✅ Sales & Platform
CRM management, system uptime, DevOps, Garmin API integration
✅ Marketing & Content
Brand messaging, digital assets, campaign execution
First phase of Utah SOC launch. All costs include 25% burden rate.
| ROLE | ANNUAL SALARY | HEADCOUNT | MONTHLY COST |
|---|---|---|---|
| Chief Operating Officer / Site Director | $160,000 | 1 | $13,333 |
| Executive Assistant / Chief of Staff | $75,000 | 1 | $6,250 |
| Clinical Operations Coordinator | $85,000 | 1 | $7,083 |
| SOC Director | $150,000 | 1 | $12,500 |
| Operations Manager | $120,000 | 1 | $10,000 |
| Customer Service Supervisor | $75,000 | 2 | $12,500 |
| Customer Service Representative | $50,000 | 6 | $25,000 |
| Technical Support Supervisor | $85,000 | 1 | $7,083 |
| Technical Support Specialist | $65,000 | 4 | $21,667 |
| QA Analyst | $70,000 | 2 | $11,667 |
| Training Coordinator | $65,000 | 1 | $5,417 |
| Phase 1 Subtotal (18 FTE) | - | 18 | $105,834/mo |
| With 25% Burden Rate | $132,292/mo | ||
Expansion begins Month 30. Adds 10 more FTE to the existing 18 from Phase 1.
| ROLE | ANNUAL SALARY | HEADCOUNT | MONTHLY COST |
|---|---|---|---|
| Customer Service Rep (Phase 2 Addition) | $50,000 | 4 | $16,667 |
| Technical Support Specialist (Additional) | $65,000 | 3 | $16,250 |
| Data Analyst | $80,000 | 2 | $13,333 |
| Workforce Manager | $90,000 | 1 | $7,500 |
| Phase 2 Additions (+10 FTE) | - | +10 | $53,750/mo |
| Total Phase 1+2 (28 FTE) with 25% Burden | $199,479/mo | ||
Final expansion at Month 36. Reaches full 38 FTE capacity.
| ROLE | ANNUAL SALARY | HEADCOUNT | MONTHLY COST |
|---|---|---|---|
| Senior Analyst | $95,000 | 2 | $15,833 |
| Customer Service Rep (Phase 3 Addition) | $50,000 | 5 | $20,833 |
| IT Support | $75,000 | 2 | $12,500 |
| Compliance Specialist | $85,000 | 1 | $7,083 |
| Phase 3 Additions (+10 FTE) | - | +10 | $56,250/mo |
| Total Phase 1+2+3 (38 FTE) with 25% Burden | $269,792/mo | ||
Phase Activation Timeline
- Phase 1 (18 FTE): Activated January 2028 — Post-clinical trial publication
- Phase 2 (28 FTE): Activated July 2028 — +10 FTE upon new monthly subscriber scale to 12,000+
- Phase 3 (38 FTE): Activated January 2029 — +10 FTE upon new monthly subscriber scale to 20,000+
Operational Readiness Factors
- Base salaries + 25% burden rate (benefits, payroll tax, insurance, facilities overhead)
- 24/7 operations in Phase 3 require night/weekend differential pay
- Career progression: Analyst → Supervisor → Manager pathways to retain talent
- Include 10-15% buffer for bonuses, overtime, equity incentives
Beyond core customer service and technical support, these roles support executive operations, regulatory compliance, and platform infrastructure.
| Role | Description | Salary Range (UT Market) | FTE — Phase 1 | FTE — Phase 2 | FTE — Phase 3 |
|---|---|---|---|---|---|
| Facilities / IT Infrastructure Manager | Manages internal IT, device provisioning, SOC secure systems, network support, and physical infrastructure. | $70K – $90K | 1 | 1 (plus vendors) | 2 |
| Sales Operations Coordinator | Oversees CRM usage, sales process flow, reporting dashboards, channel partner sales logistics. | $55K – $75K | 1 | 2 | 3 |
| Marketing / Content Manager | Develops digital assets, campaign content, collateral, brand messaging; coordinates internal and agency efforts. | $65K – $85K | — | 0.5 – 1 | 2 |
| Web / Platform Support Engineer | Maintains system uptime, incident response, Garmin integration, DevOps alerts, and backend support. | $80K – $100K | 1 | 2 | 3 |
| Regulatory & Compliance Officer | Ensures HIPAA, CMS, VA, and FDA alignment, manages audits, labeling, and documentation protocols. | $40K – $60K (0.5 FTE) to $100K full-time | 0.5 | 1 | 2 |
Visual representation of phased staffing ramp from 0 → 18 → 28 → 38 FTE
Debt information from the Assumptions tab.
Complete 36-month financial table calculated from the Assumptions tab. ✅ All formula errors FIXED.
All figures are in USD, including OptiRTP Limited (NZ) costs converted at the current NZD/USD exchange rate.
See Overview tab for full explanation of dual-entity funding structure.
All figures in USD. OptiRTP Limited (NZ) costs are converted from NZD at the exchange rate specified in Assumptions. License Rev shows the $30/sub/month fee OptiRTP receives from Resonote. Net OptiRTP = Costs minus License Revenue.
| Month | New Subs | Churn | Active Subs | Revenue | OptiRTP Costs | License Rev | Net OptiRTP | Resonote | Clinical | IRD Paydown | Total Costs | Cash Flow | Cash Balance |
|---|
